ReviewJournal of enzyme inhibition and medicinal chemistry2026
Molecular insights into triazole-based compounds for triple-negative breast cancer treatment.
Review in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype lacking oestrogen, progesterone, and HER2 receptors, thus limiting the effectiveness of targeted therapies. Triazole compounds have emerged as promising anticancer agents because of their structural versatility, chemical stability, and ability to interact with multiple biological targets. This review summarises the chemistry, biological significance, and therapeutic potential of triazole derivatives against TNBC. It highlights key anticancer mechanisms, including apoptosis induction, cell cycle arrest, inhibition of angiogenesis and metastasis, and modulation of major oncogenic signalling pathways. The review also compares synthetic and naturally derived triazole compounds, emphasising structure-activity relationships and evidence from preclinical studies. In addition, it discusses the contribution of computational approaches, including molecular docking, virtual screening, and predictive modelling, to accelerate triazole-based drug discovery. Overall, this review underscores the potential of triazole pharmacophores as effective therapeutic candidates for TNBC and provides directions for future research to overcome therapeutic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.